Dendritic cells and hepatocellular carcinoma
- PMID: 25611258
Dendritic cells and hepatocellular carcinoma
Abstract
Hepatocellular carcinoma (HCC) represents a major health burden in the modern world. Because current treatment options for HCC are capable of providing good survival rates to only a limited number of patients, new therapeutic opportunities should be looked upon. The particularities of dendritic cells (DC) populations existing in the liver, and their consecutive selective activation of certain immunotolerant T-cell subgroups, account for the high success rate of allogeneic hepatic transplantation, currently the most efficient treatment for HCC. The particularities of dendritic cells (DCs) populations existing in the liver, and their consecutive selective activation of certain immunotolerant T-cell subgroups, account for the high success rate of allogeneic hepatic transplantation for HCC. These molecular mechanisms also open new paths towards cancer preventing and cancer curative vaccines, as well as successful immunotherapy. Our aim was to summarize the main aspects of the biology of DCs populations, especially those present in the liver, and to draw attention to their current and future roles in the curative treatment of hepatocarcinoma.
Similar articles
-
Immunotherapy for hepatocellular carcinoma.Drug Discov Ther. 2015 Oct;9(5):363-71. doi: 10.5582/ddt.2015.01054. Drug Discov Ther. 2015. PMID: 26632545 Review.
-
Efficient generation of highly immunocompetent dendritic cells from peripheral blood of patients with hepatitis C virus-related hepatocellular carcinoma.Int Immunopharmacol. 2014 Aug;21(2):346-53. doi: 10.1016/j.intimp.2014.05.023. Epub 2014 Jun 2. Int Immunopharmacol. 2014. PMID: 24893118
-
Potential therapeutic value of dendritic cells loaded with NY‑ESO‑1 protein for the immunotherapy of advanced hepatocellular carcinoma.Int J Mol Med. 2013 Dec;32(6):1366-72. doi: 10.3892/ijmm.2013.1510. Epub 2013 Sep 27. Int J Mol Med. 2013. PMID: 24085111
-
Induction of specific cytolytic T lymphocytes using fusions of hepatocellular carcinoma (HCC) patient-derived dendritic cells and allogeneic HCC cell line.Hepatogastroenterology. 2008 Jan-Feb;55(81):155-9. Hepatogastroenterology. 2008. PMID: 18507097
-
Dendritic cell as therapeutic vaccines against tumors and its role in therapy for hepatocellular carcinoma.Cell Mol Immunol. 2006 Jun;3(3):197-203. Cell Mol Immunol. 2006. PMID: 16893500 Review.
Cited by
-
Immunotherapy for hepatocellular carcinoma: A promising therapeutic option for advanced disease.World J Hepatol. 2022 Oct 27;14(10):1862-1874. doi: 10.4254/wjh.v14.i10.1862. World J Hepatol. 2022. PMID: 36340753 Free PMC article. Review.
-
Immunotherapeutic Approaches for Treating Hepatocellular Carcinoma.Cancers (Basel). 2022 Oct 13;14(20):5013. doi: 10.3390/cancers14205013. Cancers (Basel). 2022. PMID: 36291797 Free PMC article. Review.
-
Interleukin-2 inducible T-cell kinase: a potential prognostic biomarker and tumor microenvironment remodeling indicator for hepatocellular carcinoma.Aging (Albany NY). 2021 Jul 19;13(14):18620-18644. doi: 10.18632/aging.203306. Epub 2021 Jul 19. Aging (Albany NY). 2021. PMID: 34282055 Free PMC article.
-
Patterns of dendritic cell and monocyte subsets are associated with disease severity and mortality in liver cirrhosis patients.Sci Rep. 2021 Mar 15;11(1):5923. doi: 10.1038/s41598-021-85148-y. Sci Rep. 2021. PMID: 33723292 Free PMC article.
-
Immunity as Cornerstone of Non-Alcoholic Fatty Liver Disease: The Contribution of Oxidative Stress in the Disease Progression.Int J Mol Sci. 2021 Jan 4;22(1):436. doi: 10.3390/ijms22010436. Int J Mol Sci. 2021. PMID: 33406763 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical